At the current time, there are few effective pharmacotherapy options for posttraumatic stress
disorder (PTSD), and no medication strategies targeted towards PTSD prophylaxis. This in …

This chapter discussed how neuroendocrine findings in posttraumatic stress disorder
(PTSD) potentially inform hypothalamic-pituitary-adrenal (HPA) alterations in PTSD and …

Post-traumatic stress disorder is a severe, debilitating mental disorder with multiple
symptoms that span biological systems and present with medical comorbidities. This …

Posttraumatic stress disorder (PTSD) is prevalent, disabling, and frequently becomes
chronic. Despite this, only two selective serotonergic reuptake inhibitors have been …

The acute stress response includes activation of the hypothalamic‐pituitary‐adrenal (HPA)
axis, which leads to the release of cortisol, a glucocorticoid. Through negative feedback …

Posttraumatic stress disorder (PTSD) is a highly disabling psychiatric condition that may
arise after exposure to acute and severe trauma. It is a highly prevalent mental disorder …

Posttraumatic stress disorder (PTSD) is a pervasive issue within military populations, with
approximately 29% of post-9/11 service members experience PTSD at some point in their …

The findings from investigations of the neuroendocrinology of posttraumatic stress disorder
(PTSD) have highlighted alterations that have not historically been associated with …

Posttraumatic stress disorder (PTSD) is a prevalent, disabling, and often chronic condition
that may develop following exposure to a traumatic event. Despite the immense social and …

Biological markers, particularly endocrine measurements, are increasingly being integrated
into clinical psychological research. We introduce a systematic framework that classifies …